[en] The European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain, was a platform for scientific discussion of the highest quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses some of the high-quality research studies presented at that Congress, with a focus on airway diseases, including asthma, COPD, small airways, bronchiectasis and cough, presented through the Airway Diseases, Asthma and COPD Assembly (Assembly 5) of the ERS. The authors establish the key take-home messages of these studies, compare their findings and place them into context of current understanding.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Lahousse, Lies ; Dept of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent
Bahmer, Thomas; University Hospital Schleswig-Holstein Campus Kiel, Dept for Internal Medicine I,
Cuevas-Ocaña, Sara; Wolfson Centre for Stem cells, Tissue Engineering and Modelling (STEM), Dept of
Flajolet, Pauline; Respiratory Pharmacology, National Heart and Lung Institute, Imperial College
Mathioudakis, Alexander G ; Division of Infection, Immunity and Respiratory Medicine, School of Biological ; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS
McDonnell, Melissa; Dept of Respiratory Medicine, Galway University Hospitals, Galway, Ireland.
Uller, Lena; Respiratory Immunopharmacology, Dept of Experimental Medical Science, Lund
Schleich, FLorence ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Dortas Junior, Sergio ; Serviço de Imunologia, Hospital Universitário Clementino Fraga Filho ; Universidade Iguaçu (UNIG), Nova Iguaçu, Brazil.
Idzko, Marco; Dept of Pneumology, Medical University of Vienna, Vienna, Austria.
Singh, Dave; Medicines Evaluation Unit, University of Manchester, Manchester University NHS
Ricciardolo, Fabio L M; Dept of Clinical and Biological Sciences, Azienda Ospedaliera Universitaria (AOU)
Adcock, Ian M; National Heart and Lung Institute, Imperial College London, London, UK.
Usmani, Omar; National Heart and Lung Institute, Imperial College London, London, UK.
Spanevello, Antonio; University of Insubria, Istituti Clinici Scientifici Maugeri, IRCCS, Varese,
Bonvini, Sara J; Respiratory Pharmacology, National Heart and Lung Institute, Imperial College
Andersson C, Bonvini SJ, Horvath P, et al. Research highlights from the 2017 ERS International Congress: airway disease in focus. ERJ Open Res 2018; 4: 00163-2017.
Schleich F, Bikov A, Mathioudkis AG, et al. Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Res 2019; 5: 00225-2018.
Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2019; 55: 1900588.
Ramos Ramirez P, Noreby M, Olsson HK, et al. Budesonide-induced decrease of IL-5 production does not affect allergen-induced bronchoconstriction or AHR in a novel guinea pig asthma model. Eur Respir J 2019; 54: Suppl. 63, PA4081.
Bonvini SJ, Adcock JJ, Kobold NK, et al. A novel role for TRPM3 in Airway Smooth Muscle Contraction. Eur Respir J 2019; 54: Suppl. 63, OA4956.
Yarova PL, Stewart AL, Sathis V, et al. Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma. Sci Transl Med 2015; 7: 1–11.
Huang P, Mansfield B, Du X, et al. Therapeutic effects of topical calcilytic in IgE/Th2 and alarmin-driven surrogates of human asthma. Eur Respir J 2019; 54: Suppl. 63, OA4958.
Kim SR, Lee YC, Park HJ, et al. An inhaled IGFBP-3 peptide attenuates steroid-resistant neutrophilic bronchial asthma through modulation of ER stress. Eur Respir J 2019; 54: Suppl. 63, OA4955.
Da Palma RK, Fratini P, Schiavo Matias GS, et al. Equine lung decellularization: a potential approach for in vitro modeling the role of the extracellular matrix in asthma. J Tissue Eng 2018; 9: 2041731418810164.
Palma R, Cereta A, Gulmaraes L, et al. Characterisation of axellular lung scaffolds derived from equine asthma model. Eur Respir J 2019; 54: Suppl. 63, PA599.
Remot A, Descamps D, Noordine ML, et al. Bacteria isolated from lung modulate asthma susceptibility in mice. ISME J 2017; 11: 1061–1074.
Barbé-Tuana F, Grun L, Pitrez P, et al. Association between shorter telomeres’ length and eotaxin-1 in children with severe asthma, an indicative of accelerated aging. Eur Respir J 2019; 54: Suppl. 63, OA3594.
Gibbs CJ, Coutts II, Lock R, et al. Premenstrual exacerbation of asthma. Thorax 1984; 39: 833–836.
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.
Robijn A, Jensen M, Mclaughlin K, et al. Evaluating inhaled corticosteroid use among pregnant women with asthma: systematic review and meta-analysis. Eur Respir J 2019; 54: Suppl. 63, PA2558.
Pavlidis S, Takahashi K, Ng Kee Kwong F, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J 2019; 53: 1800938.
Ostling J, van Geest M, Schfied JPR, et al. IL-17-high asthma with features of a psoriasis immunophenotype. JACI 2019; 144: 1198–1213.
Kuo CS, Pavlidid S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 2017; 49: 1602135.
Kalinauskaite-Zukauske V, Januskevicius A, Jaulaityte I, et al. Thymic stromal lymphopoietin, but not ezrin, could be an early biomarker of airway epithelial dysfunction in acute allergic asthma. Eur Respir J 2019; 54: Suppl. 63, PA1702.
James A, Gomez C, Thorngren JO, et al. Matrix metalloproteinases in serum and sputum reflect distinct processes of relevance to asthma. Eur Respir J 2019; 54: Suppl. 63, OA3802.
Juusela M, Aaltonen V, Sarna S, et al. Particles in exhaled air (PExA) method – repeatability in children. Eur Respir J 2019; 54: Suppl. 63, PA1705.
Brinkman P, Wagener AH, Hekking PP, et al. Identification and prospective stability of electronic node (eNose)-derived inflammatory phenotypes in patients with severe asthma. JACI 2019; 143: 1811–1820.
Schleich FN, Zanella D, Stefanuto PH, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 2019; 200: 444–453.
Jones M, Neville D, Gates J, et al. EXhaled Hydrogen peroxide As a marker of Lung diseasE-the EXHALE 1A study. Eur Respir J 2019; 54: Suppl. 63, PA1712.
de Vries R, Dagelet Y, Dijkers E, et al. Late Breaking Abstract-Technical validation of breath analysis by eNose in disease diagnosis: Tidal breathing vs. vital capacity manoeuvre. Eur Respir J 2019; 54: Suppl. 63, PA3904.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. www.ginasthma. org.
Reddel H, Bateman ED, Fitzgerald M, et al. Exacerbation risk after night-time walking due to asthma in SYGMA 1. Eur Respir J 2019; 54: Suppl. 63, PA3715.
Fitzgerald M, O’Byrne P, Bateman ED, et al. Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. Eur Respir J 2019; 54: Suppl. 63, PA3716.
Hardy J, Baggott C, Fingleton J, et al. Late Breaking Abstract-Open label trial of budesonide/formoterol reliever therapy in milk asthma. Eur Respir J 2019; 54: Suppl. 63, OA5332.
Janson C, Nwaru B, Hasvold LP, et al. Late Breaking Asthma-SABA overuse and risk of mortality in a nationwide Swedish asthma cohort (HERA). Eur Respir J 2019; 54: Suppl. 63, OA2105.
Janson C, Nwaru B, Hasvold LP, et al. Use of short-acting beta-2 agonists (SABA) and exacerbations in a nationwide Swedish asthma cohort (HERA). Eur Respir J 2019; 54: Suppl. 63, PA2554.
Horne R, Chan A, Haughney J, et al. Late Breaking Abstract-Identifying and addressing patient beliefs driving SABA use and over reliance. Eur Respir J 2019; 54: Suppl. 63, OA5333.
Bodina R, Grinovero M, Corsico A, et al. Digital Therapy in the treatment of asthma and COPD-Epidemiology of development and use of an emerging health technology in Respiratory Medicine. Eur Respir J 2019; 54: Suppl. 63, PA735.
Khusial R, Honkoop P, Usmani O, et al. myAirCoach: mHealth assisted self management in patients with uncontrolled asthma, a randomized control trial. Eur Respir J 2019; 54: Suppl. 63, PA745.
Lahousse L, Vanoverschelde A. Improving inhaler technique in asthma/COPD by mHealth: a Belgian RCT. Eur Respir J 2019; 54: Suppl. 63, PA2235.
Bischoff E, Boer L, Van Der Heijden M, et al. A smart MHealth tool versus a paper action plan to support self management of COPD exacerbations: a randomised controlled trial. Eur Respir J 2019; 54: Suppl. 63, PA2238.
Sulku J, Jansson C, Melhus H, et al. Critical handling errors with dry powder, metered dose and soft mist inhaler devices in an observational COPD study. Eur Respir J 2019; 54: Suppl. 63, PA4258.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343.
Daley-Yates P, Brealey N, Kumar B, et al. Dose responses for topical efficacy and systematic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone proprionate (FP and budesonide (BUD) in asthmatic subjects. Eur Respir J 2019; 54: Suppl. 63, OA2106.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–1197.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–1207.
Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5: 390–400.
Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016; 150: 789–798.
Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125–1132.
Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355–366.
Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma. Chest 2016; 150: 799–810.
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128–2141.
Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376: 2448–2458.
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115–2127.
Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879–890.
Harrison T, Canonica GW, Gemzoe K, et al. Late Breaking Abstract-Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study. Eur Respir J 2019; 54: Suppl. 63, PA1659.
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388: 31–44.
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475–2485.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486–2496.
Bleecker ER, Li X, Newbold P, et al. Benralizumab treatment and SARP cluster analysis. Eur Respir J 2019; 54: Suppl. 63, PA1659.
Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med 2019; 381: 1257–1266.
Soriano JB, Alfageme I, Miravitlles M, et al. A new study of the prevalence of COPD in Spain: EPISCAN II. Eur Respir J 2019; 54: Suppl. 63, PA3317.
Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 67–86.
Wijnant S, De Roos E, Kavousi M, et al. Preserved ratio impaired spirometry (PRISm) and mortality: the Rotterdam Study. Eur Respir J 2019; 54: Suppl. 63, PA4421.
Dahl M, Landt E, Colak Y, et al. Impact of chronic cough in individuals with COPD: a population-based cohort study. Eur Respir J 2019; 54: Suppl. 63, PA4427.
Vikjord S, Mai XM, Brumpton B, et al. The association of anxiety and depression with mortality, symptom burden and health care utilization in a COPD cohort. The HUNT Study, Norway. Eur Respir J 2019; 54: Suppl. 63, PA4428.
Shafuddin E, Chang C, Hancox R. Cardiac biomarkers and outcomes of COPD exacerbations. Eur Respir J 2019; 54: Suppl. 63, PA4290.
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017; 49: 1700214.
Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/ American Thoracic Society Guideline. Eur Respir J 2017; 49: 1600791.
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662–671.
Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev 2017; 26: 160073.
Kostikas K, Papathanasiou E, Papaioannou A, et al. Blood eosinophils as predictor of outcomes in hospitalized COPD exacerbations: results from a prospective study. Eur Respir J 2019; 54: Suppl. 63, OA2147.
Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193: 965–974.
Calverley PMA, Jenkins C, Wedzicha JA. Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. Eur Respir J 2019; 54: Suppl. 63, OA 2149.
Mathioudakis A, Foden P, Vestbo J. Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Eur Respir J 2018; 52: Suppl. 62, OA2125.
Soyseth V, Kononova N, Einvik G. Cardiac troponin increases in COPD patients hospitalised for pneumonias as well as exacerbations. Eur Respir J 2019; 54: Suppl. 63, PA4286.
Shafuddin E, Chang C, Hancox RJ. Cardiac biomarkers and outcomes of COPD exacerbations. Eur Respir J 2019; 54: Suppl. 63, PA4290.
Mathioudakis AG, Janner J, Moberg M, et al. A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. ERJ Open Res 2019; 5: 00136-2019.
Lahousse LL, Vanfleteren LEGW. When the heart steals your breath away. Respiration 2019; 97: 199–201.
Tine M, Turato G, Lokar Oliani K, et al. Acute exacerbation of COPD in emergency room: just COPD exacerbations? Eur Respir J 2019; 54: Suppl. 63, PA5220.
Shafuddin E, Chang C, Hancox RJ. Cardiac function during exacerbations of COPD assessed using cardiac MRI. Eur Respir J 2019; 54: Suppl. 63, OA1919.
Ergan B, Oczkowski S, Rochwerg B, et al. European Respiratory Society guideline on long-term home non-invasive ventilation for management of chronic obstructive pulmonary disease. Eur Respir J 2019; 54: 1901003.
Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 2017; 317: 2177–2186.
Köhnlein T, Windisch W, Köhler D, et al. Noninvasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698–705.
van den Biggelaar RJM, Hazenberg A, Cobben NAM, et al. Initiation of non-invasive home mechanical ventilation in the hospital compared with initiation at home: the Dutch Homerun trial. Eur Respir J 2019; 54: Suppl. 63, OA3826.
Duiverman ML, Bladder G, Vonk JM, et al. Home initiation of chronic high-intensity noninvasive ventilation in COPD patients with chronic hypercapnic respiratory failure: the RECONSIDER trial. Eur Respir J 2019; 54: Suppl. 63, RCT451.
Bonini M, Usmani OS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 2015; 9: 281–293.
Usmani OS, Singh D, Spinola M, et al. The prevalence of small airways disease in adult asthma: A systematic literature review. Respir Med 2016; 116: 19–27.
Postma DS, Brightling C, Baldi S, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med 2019; 7: 402–416.
Nasr A, Romberg K, Nihlen U, et al. Forced oscillation technique measuring peripheral airway involvement during mannitol challenge. Eur Respir J 2019; 54: Suppl. 63, PA354.
Trinkmann F, Götzmann J, Saur D, et al. Multiple breath washout testing in adults with pulmonary disease and healthy controls – can fewer measurements eventually be more? BMC Pulm Med 2017; 17: 185.
Trinkmann F, Lenz S, Schäfer J, et al. Multiple breath washout (MBW) testing using SF6 – feasibility and clinical applications in adults with bronchial asthma. Eur Respir J 2019; 54: Suppl. 63, PA349.
Singer F, Abbas C, Yammine S, et al. Abnormal small airways function in children with mild asthma. Chest 2014; 145: 492–499.
Skylogianni E, Triga M, Bolis K, et al. The march from subclinical small-airways dysfunction to asthma in children with allergic rhinitis. Eur Respir J 2019; 54: Suppl. 63, PA965.
Skylogianni E, Triga M, Douros K, et al. Small-airway dysfunction precedes the development of asthma in children with allergic rhinitis. Allergol Immunopathol (Madr) 2018; 46: 313–321.
McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365: 1567–1575.
Gao L, Wu Y, Wang H, et al. Forced oscillation technique for sensitive detection of early-stage chronic obstructive pulmonary disease. Eur Respir J 2019; 54: Suppl. 63, PA2631.
Gove K, Conway J, Ostridge K, et al. Comparison of small airways disease measures between frequent and infrequent COPD exacerbators. Eur Respir J 2019; 54: Suppl. 63, PA1120.
Trinkmann F, Gawlitza J, Schäfer J, et al. Novel lung function tests can improve phenotyping and differential therapy in COPD. Eur Respir J 2019; 54: Suppl. 63, PA3379.
Shirai T, Hirai K, Gon Y, et al. Forced oscillation technique may identify severe asthma. Eur Respir J 2019; 54: Suppl. 63, PA2632.
Nasr A, Jarenbäck L, Bjermer L, et al. Assessment of expiratory vs inspiratory resistance and reactance using FOT as a measure of air trapping. Eur Respir J 2019; 54: Suppl. 63, PA2634.
Ong-Salvador R, Dijkers E, Van Steenwijk R. The role of R5-19 in assessing peripheral airway obstruction. Eur Respir J 2019; 54: Suppl. 63, PA1117.
Lipworth B, Manoharam A, Anderson W. Unlocking the quiet zone:the small airway asthma phenotype. Lancet Respir Med 2014; 2: 497–506.
Bazan-Socha S, Zuk J, Kozlik P, et al. Relationship of airway structural changes and lung function abnormalities with blood and BAL biomarkers in asthma. Eur Respir J 2019; 54: Suppl. 63, OA505.
Kozlik P, Zuk J, Bartyzel S, et al. The relationship of airway structural changes to blood and bronchoalveolar lavage biomarkers, and lung function abnormalities in asthma. Clin Exp Allergy 2019; 50: 15–28.
Li H, Yan LP, Wang K, et al. Association between ADAM33 polymorphisms and asthma risk: a systematic review and meta-analysis. Respir Res 2019; 20: 38.
Yang L, Liu BC, Liu T, et al. Microbiome in lower respiratory tract of steroid-free patients with asthma. Eur Respir J 2019; 54: Suppl. 63, PA533.
Huang Y, Opron K, Erb-Downward J, et al. Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. Eur Respir J 2019; 54: Suppl. 63, OA3580.
Maestre D, Huff RD, Schwartz C, et al. Di-butyl phthalate (DBP) augments allergen-induced lung function decline and alters lower airway innate immunology in crossover human study. Eur Respir J 2019; 54: Suppl. 63, PA1992.
Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med 2005; 172: 1497–1504.
Hillyer EV, Price DB, Chrystyn H, et al. Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal. J Aerosol Med Pulm Drug Deliv 2018; 31: 111–113.
Usmani OS. Small-airway disease in asthma: pharmacological considerations. Curr Opin Pulm Med 2015; 21: 55–67.
Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019; 394: 1737–1749.
Virchow JC, Paggiaro P, Canonica WG, et al. Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study. Eur Respir J 2019; 54: Suppl. 63, PA3719.
Canonica WG, Virchow JC, Singh D, et al. Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study. Eur Respir J 2019; 54: Suppl. 63, OA5339.
Topole E, Usmani O, Mignot B, et al. Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI). Eur Respir J 2019; 54: Suppl. 63, PA3167.
Sadiq MW, Holz O, Ellinghusen B, et al. Spatial pharmacokinetics of inhaled drugs in human lung – evaluation of regional lung targeting by direct sampling of epithelial lining fluid. Eur Respir J 2019; 54: Suppl. 63, OA2103.
Skogberg G, Jackson S, Fihn BM, et al. RNAscope in situ hybridization allows spatial estimation of free drug exposure through quantification of drug induced gene expression. Eur Respir J 2019; 54: Suppl. 63, PA3377.
Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet 2018; 392: 880–890.
Chalmers JD, Moffitt KL, Suarez-Cuartin SO, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017; 195: 1384–1393.
Shoemark A, Cant E, Carreto L, et al. A point of care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J 2019; 54: Suppl. 63, OA4947.
Finch S, Shoemark A, Dicker AJ, et al. Characterisation of sputum pregnancy zone protein in bronchiectasis. Eur Respir J 2019; 54: Suppl. 63, PA2167.
Smith A, Lang J, Keir HR, et al. Heparin binding protein in sputum compromises epithelial defence and relates to bronchiectasis severity. Eur Respir J 2019; 54: Suppl. 63, PA2172.
McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med 2016; 4: 969–979.
Raats D, Decaesteker T, Fogelström M, et al. Cross-sectional evaluation of serum and sputum calprotectin in bronchiectasis disease monitoring. Eur Respir J 2019; 54: Suppl. 63, PA2678.
Scioscia G, Amaro R, Alcaraz V, et al. The role of systemic markers of inflammation in bronchiectasis. Eur Respir J 2019; 54: Suppl. 63, PA2884.
Çetinkaya A, Uysal MA, Niksarlıoglu EY, et al. Can Neutrophil/lymphocyte Ratio, C-reactive protein (CRP) and Procalcitonin predict the hospitalisation time in patients with lower tract respiratory infections? Eur Respir J 2019; 54: Suppl. 63, PA3849.
Méndez R, Moscardó A, Latorre A, et al. Platelet activation correlates with disease severity in bronchiectasis. Eur Respir J 2019; 54: Suppl. 63, PA2168.
Shoemark A, Smith A, Giam A, et al. Inflammatory molecular endotypes in bronchiectasis. Eur Respir J 2019; 54: Suppl. 63, PA2170.
Huang JT, Dicker A, Shoemark A, et al. Endotyping of COPD, bronchiectasis and their overlap syndrome by integrated sputum proteome/microbiome. Eur Respir J 2019; 54: Suppl. 63, OA473.
Keir HR, Fong CJ, Tan B, et al. Neutrophil extracellular traps and the lung microbiome in bronchiectasis. Eur Respir J 2019; 54: Suppl. 63, OA5142.
Thng KX, Mac Aogáin M, Ali NABM, et al. Viral prevalence in stable bronchiectasis: analysis of the Cohort of Asian and Matched European Bronchiectasis (CAMEB). Eur Respir J 2019; 54: PA2875.
Gramegna A, Aliberti S, Zucchetti S, et al. Respiratory viruses in stable state bronchiectasis. Eur Respir J 2019; 54: Suppl. 63, PA2171.
Burgel P, Polverino E, Harworth C, et al. Risk factors for new P. aeruginosa isolation in bronchiectasis-data from the European Bronchiectasis Registry (EMBARC). E Eur Respir J 2019; 54: Suppl. 63, PA2163.
Ringshausen FC, Chalmers JD, Polverino E, et al. New isolation of non-tuberculous mycobacteria in patients with bronchiectasis-data from the European Bronchiectasis Registry (EMBARC). Eur Respir J 2019; 54: Suppl. 63, PA2937.
Nuñez Garcia L, Zambrano Chacón MA, Gotera Rivera C, et al. Prevalence of bronchiectasis in a lung cancer screening program. Eur Respir J 2019; 54: Suppl. 63, PA3025.
Sanchez-Carpintero Abad M, Zulueta JJ, De Torres JP, et al. Prevalence and burden of bronchiectasis in a lung cancer screening program. Eur Respir J 2019; 54: Suppl. 63, PA2902.
Aliberti S, Menendez R, Blasi F, et al. Determinants of survival in the European Bronchiectasis Registry (EMBARC). Eur Respir J 2019; 54: OA4949.
Herrero Cortina B, San Miguel-Pagola M, Francín-Gallego M, et al. Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis: a randomised controlled trial. Eur Respir J 2019; 54: Suppl. 63, OA4948.
Wynne S, Patel S, Barker RE, et al. The effect of pulmonary rehabilitation (PR) on anxiety and depression symptoms in bronchiectasis: a propensity-matched study. Eur Respir J 2019; 54: Suppl. 63, PA663.
Terpstra L, Altenburg J, Mohamed Hoesein F, et al. The effect of maintenance azithromycin on radiological features in patients with bronchiectasis. E Eur Respir J 2019; 54: Suppl. 63, PA2865.
Altenburg J, Chalmers JD, Lonergan M, et al. Long term macrolide antibiotics for the treatment of bronchiectasis in adults – individual participant data meta-analysis. Eur Respir J 2019; 54: Suppl. 63, OA4945.
Terpstra L, Vijverberg S, Sabogal Piñeros Y, et al. The effect of azithromycin on sputum inflammatory markers in bronchiectasis – analysis of a randomised controlled trial. Eur Respir J 2019; 54: Suppl. 63, OA4946.
Sabogal Piñeros YS, Altenburg J, Vijverberg S, et al. Explorative analyses of inflammatory pathways and the effect of azithromycin in bronchiectasis patients. Eur Respir J 2019; 54: Suppl. 63, PA2671.
Perez J, Polverino E, Alvares A, et al. Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort. Eur Respir J 2019; 54: Suppl. 63, PA4580.
Martinho Pereira PS, Gomes L, Costa J, et al. Multidrug resistant bacteria in bronchiectasis exacerbations. Eur Respir J 2019; 54: Suppl. 63, PA2872.
French CL. Impact of chronic cough on quality of life. Arch Intern Med 1998; 158: 1657–1661.
Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2014; 14: 61255–1.
Niimi A, Ishirhara H, Hilda H, et al. Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough. Eur Respir J 2019; 54: Suppl. 63, RCT452.
Smith J, Ballantyne E, Kerr M, et al. The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial. Eur Respir J 2019; 54: Suppl. 63, PA600.
Brannan J, Nurmi H, Latti A, et al. Mannitol and citric acid tests similarly identify subjects with chonic cough. Eur Respir J 2019; 54: Suppl. 63, OA3287.
Holmes J, Heaney L, Birring S, et al. Association between cough frequency, health status and Th2 inflammation in severe asthma. Eur Respir J 2019; 54: Suppl. 63, PA2720.
Raemdonck K, de Alba J, Birrell MA, et al. A role for sensory nerves in the late asthmatic response. Thorax 2012; 67: 19–25.
Van de Berg MPM, Nikboer-Brinksma S, Bos S, et al. A novel TRPA1 antagonist inhibits ovalbumin-induced bronchoconstriction in guinea pig models. Eur Respir J 2019; 54: Suppl. 63, PA4210.
Birrell MA, Belvisi MG, Grace M, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. AJRCCM 2009; 180: 1042–1047.
